Treatment of pituitary dependent Cushing’s disease with the multi-receptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial - Boscaro, M; Ludlam, W H; Atkinson, B (J Clin Endocrinol Metab, 2009)
et al.